Aktis Oncology, Inc. Common stock Cash Flow Conversion Efficiency
Aktis Oncology, Inc. Common stock cash flow conversion efficiency. Based on the latest financial reports, Aktis Oncology, Inc. Common stock (AKTS) has a cash flow conversion efficiency ratio of 0.146x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.80 Million) by net assets ($-87.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Aktis Oncology, Inc. Common stock (2014–2024)
Cash flow conversion efficiency of Aktis Oncology, Inc. Common stock from 2014 to 2024. This chart illustrates how Aktis Oncology, Inc. Common stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Aktis Oncology, Inc. Common stock for real-time trading data and today's change.
Aktis Oncology, Inc. Common stock Cash Flow Conversion Ratio Explained
Aktis Oncology, Inc. Common stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Aktis Oncology, Inc. Common stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aktis Oncology, Inc. Common stock ranked by their cash flow conversion efficiency. Also see Aktis Oncology, Inc. Common stock (AKTS) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hainan Shennong Technology Co Ltd
SHE:300189
|
0.008x |
|
Afcon Holdings Ltd
TA:AFHL
|
-0.005x |
|
Grupo Posadas S.A.B. de C.V
MX:POSADASA
|
0.097x |
|
Diversified United Investment Ltd
AU:DUI
|
0.018x |
|
Hangzhou Greenda Electronic Materials Co Ltd
SHG:603931
|
0.028x |
|
SGSG Science&technology Co Ltd Zhuhai
SHE:300561
|
0.008x |
|
Hunan Jiudian Pharmaceutical Co Ltd
SHE:300705
|
0.066x |
|
Latham Group Inc
NASDAQ:SWIM
|
0.130x |
Annual Cash Flow Conversion Efficiency for Aktis Oncology, Inc. Common stock (2014–2024)
The table below shows the annual cash flow conversion efficiency of Aktis Oncology, Inc. Common stock from 2014 to 2024. Review AKTS FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-87.80 Million | $14.76 Million | -0.168x | -123.79% |
| 2024-06-30 | $-57.09 Million | $-40.35 Million | 0.707x | +9.06% |
| 2023-12-31 | $-46.31 Million | $-30.00 Million | 0.648x | +224.67% |
| 2023-06-30 | $86.24 Million | $-44.82 Million | -0.520x | -155.14% |
| 2022-12-31 | $-19.23 Million | $-18.12 Million | 0.943x | +315.70% |
| 2022-06-30 | $103.43 Million | $-45.20 Million | -0.437x | 0.00% |
| 2021-12-31 | $103.43 Million | $-45.20 Million | -0.437x | -74.72% |
| 2021-06-30 | $117.41 Million | $-29.36 Million | -0.250x | +51.29% |
| 2020-12-31 | $41.49 Million | $-21.30 Million | -0.513x | 0.00% |
| 2020-06-30 | $41.49 Million | $-21.30 Million | -0.513x | +24.57% |
| 2019-12-31 | $25.95 Million | $-17.67 Million | -0.681x | 0.00% |
| 2019-06-30 | $25.95 Million | $-17.67 Million | -0.681x | +33.61% |
| 2018-12-31 | $13.85 Million | $-14.20 Million | -1.025x | 0.00% |
| 2018-06-30 | $13.85 Million | $-14.20 Million | -1.025x | -177.37% |
| 2017-12-31 | $15.01 Million | $-5.55 Million | -0.370x | 0.00% |
| 2017-06-30 | $15.01 Million | $-5.55 Million | -0.370x | +10.09% |
| 2016-06-30 | $2.68 Million | $-1.10 Million | -0.411x | 0.00% |
| 2015-12-31 | $2.68 Million | $-1.10 Million | -0.411x | -75.57% |
| 2015-06-30 | $4.19 Million | $-980.04K | -0.234x | 0.00% |
| 2014-12-31 | $4.19 Million | $-980.04K | -0.234x | +92.00% |
| 2014-06-30 | $9.21K | $-26.98K | -2.928x | -- |
About Aktis Oncology, Inc. Common stock
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatmen… Read more